Last reviewed · How we verify
bimatoprost eye drops
At a glance
| Generic name | bimatoprost eye drops |
|---|---|
| Sponsor | Allergan |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension (PHASE1, PHASE2)
- Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone) (PHASE3)
- Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine) (PHASE3)
- Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution (PHASE2, PHASE3)
- Stop Retinal Ganglion Cell Dysfunction Study (PHASE3)
- Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution (PHASE1, PHASE2)
- Bimatoprost as a Treatment for Graves' Orbitopathy (EARLY_PHASE1)
- Triplenex (triple Fixed Combination) Use Evaluation in Patients with Glaucoma (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |